Iftikhar Malik, MD
Endocrinology, Diabetes & Metabolism · Appleton, WINPI 1780616136
Payments from drug & device makers
What this record shows
This record is dominated by other: $6,000 of the $6,237 with a category attached, or 96.2%. Cambridge Interventional LLC accounts for 96.2% of it on its own, with 7 other manufacturers making up the rest. 2025 is the largest year on record at $6,108, more than ten times the $116 reported in 2019.
Across 8 payments — averaging $779.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cambridge Interventional LLC$6K
- Abbott$100
- Dilon Technologies, Inc.$33
- Ascendis Pharma Endocrinology Inc$29
- Tandem Diabetes Care, Inc.$26
- Sequel Med Tech, LLC$21
- plus $29 from 2 others
What the payments were for
- Food & beverage$1252%
- Education$1122%
- Other$6,00096%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cambridge Interventional LLC | 1 | $6,000 |
| Abbott | 1 | $100 |
| Dilon Technologies, Inc. | 1 | $33 |
| Ascendis Pharma Endocrinology Inc | 1 | $29 |
| Tandem Diabetes Care, Inc. | 1 | $26 |
| Sequel Med Tech, LLC | 1 | $21 |
| Medtronic | 1 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CRF$6,000
How this compares
$6,237 in reported general payments places this provider in the 85th percentile of 127 endocrinology, diabetes & metabolism providers in Wisconsin.
See all endocrinology, diabetes & metabolism providers in Wisconsin →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 82 | $96,063 |
| MounjaroTirzepatide | 68 | $87,960 |
| JardianceEmpagliflozin | 22 | $35,459 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 30 | $24,591 |
| TrulicityDulaglutide | 14 | $18,682 |
| Testosterone | 51 | $14,671 |
| Levothyroxine Sodium | 1,200 | $14,204 |
| JanuviaSitagliptin Phosphate | 20 | $13,258 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 64 | $11,141 |
| Insulin Lispro Protamine MixInsulin Lispro Protamin/Lispro | 16 | $8,179 |
| Humalog Kwikpen U-100Insulin Lispro | 24 | $7,896 |
| SynthroidLevothyroxine Sodium | 166 | $7,787 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 22 | $7,632 |
| Humulin 70/30 KwikpenInsulin Nph Hum/Reg Insulin Hm | 30 | $7,471 |
| Cinacalcet Hcl | 28 | $6,259 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Appleton
- Aron AdkinsEau Claire$349K
- Steven RabinoweRacine$344K
- Daniel Shortla Crosse$328K
- Laura AndrewsMenasha$294K
- Amy DeguemeMequon$143K
- James FindlingMenomonee Falls$78K
- Neil BinkleyMadison$76K
- Vinay PatelNeenah$64K
- Denise Teves QuallerMilwaukee$56K
- Elaine DrobnyMilwaukee$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.